دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
THANKS TO REFEREES 2023
doi : 10.1016/j.annonc.2023.11.002
Volume 35, Issue 1, January 2024, Pages 1-2
Annals of Oncology – passing the baton, raising the bar
Thomas Powles MD*
doi : 10.1016/j.annonc.2023.11.011
Volume 35, Issue 1, January 2024, Page 3
POSing the question: MARIPOSA-2, do the ends justify the means?
M. F. Chen 1 , Z. Piotrowska 2 & H. A. Yu
doi : 10.1016/j.annonc.2023.11.005
Volume 35, Issue 1, January 2024, Pages 4-6
Moving precision forward: extending next generation sequencing to operable disease in less common breast cancer subtypes
A. Thomas 1 *, R. Shatsky 2 & K. Kalinsky 3
doi : 10.1016/j.annonc.2023.10.127
Volume 35, Issue 1, January 2024, Pages 7-9
Is there a role for continuation of CDK4/6 inhibition after progression on a prior CDK4/6 inhibitor in HR+/HER2− metastatic breast cancer?
A. Giordano1,2,3 , N. U. Lin 1,2,3 , S. M. Tolaney 1,2,3 & E. L. Mayer
doi : 10.1016/j.annonc.2023.11.003
Volume 35, Issue 1, January 2024, Pages 10-14
ESMO Clinical Practice Guideline interim update on the use of targeted therapy in acute lymphoblastic leukaemia
D. Hoelzer1 , R. Bassan 2 , N. Boissel 3 , C. Roddie4 , J. M. Ribera 5 & M. Jerkeman6 , on behalf of the ESMO Guidelines Committee
doi : 10.1016/j.annonc.2023.09.3112
Volume 35, Issue 1, January 2024, Pages 15-28
Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review
A. Prelaj 1,2,3, V. Miskovic 1,2 , M. Zanitti4 , F. Trovo 2 , C. Genova 5,6 , G. Viscardi7 , S. E. Rebuzzi6,8 , L. Mazzeo1,2 , L. Provenzano1 , S. Kosta 4 , M. Favali 2 , A. Spagnoletti 1 , L. Castelo-Branco 9,10 , J. Dolezal 11 , A. T. Pearson11 , G. Lo Russo 1 , C. Proto1 , M. Ganzinelli 1 , C. Giani1 , E. Ambrosini 2 , S. Turajlic 12 , L. Au13,14,15 , M. Koopman16,3 , S. Delaloge 17,3 , J. N. Kather 18 , F. de Braud 1 , M. C. Garassino 11 , G. Pentheroudakis 9 , C. Spencer12y & A. L. G. Pedrocchi
doi : 10.1016/j.annonc.2023.10.125
Volume 35, Issue 1, January 2024, Pages 29-65
SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
H. Borghaei 1, F. de Marinis 2 , D. Dumoulin3 , C. Reynolds 4 , W. S. M. E. Theelen5 , I. Percent6 , V. Gutierrez Calderon7 , M. L. Johnson 8 , A. Madroszyk-Flandin9 , E. B. Garon10 , K. He 11 , D. Planchard 12 , M. Reck 13 , S. Popat 14 , R. S. Herbst15 , T. A. Leal16 , R. L. Shazer 17 , X. Yan17 , R. Harrigan 17 & S. Peters 18 , on behalf of the SAPPHIRE Investigators
doi : 10.1016/j.annonc.2023.10.004
Volume 35, Issue 1, January 2024, Pages 66-76
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study☆
A. Passaro 1y, J. Wang 2y, Y. Wang 3 , S.-H. Lee 4 , B. Melosky 5 , J.-Y. Shih 6 , J. Wang7 , K. Azuma 8 , O. Juan-Vidal9 , M. Cobo 10 , E. Felip11 , N. Girard12,13 , A. B. Cortot 14 , R. Califano 15 , F. Cappuzzo 16 , S. Owen 17 , S. Popat18 , J.-L. Tan 19 , J. Salinas 20 , P. Tomasini 21 , R. D. Gentzler 22 , W. N. William, Jr. 23 , K. L. Reckamp 24 , T. Takahashi 25 , S. Ganguly26 , D. M. Kowalski 27 , A. Bearz 28 , M. MacKean 29 , P. Barala 30 , A. B. Bourla31 , A. Girvin 30 , J. Greger30 , D. Millington 32 , M. Withelder 30 , J. Xie 31 , T. Sun 31 , S. Shah30 , B. Diorio 31 , R. E. Knoblauch 30 , J. M. Bauml 30 , R. G. Campelo33z & B. C. Cho34z, for the MARIPOSA-2 Investigators
doi : 10.1016/j.annonc.2023.10.117
Volume 35, Issue 1, January 2024, Pages 77-90
The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma☆
B. A. McGregor 1y, G. P. Sonpavde1,2y, L. Kwak 1 , M. M. Regan 1 , X. Gao3 , H. Hvidsten1 , C. M. Mantia 1 , X. X. Wei1 , J. E. Berchuck 1 , S. A. Berg1 , P. K. Ravi1 , M. D. Michaelson 3 , T. K. Choueiri1 & J. Bellmunt
doi : 10.1016/j.annonc.2023.09.3114
Volume 35, Issue 1, January 2024, Pages 91-97
Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer
J. W. F. Catto1,2, B. Tran3 , M. Rouprêt4 , J. E. Gschwend 5 , Y. Loriot 6 , H. Nishiyama 7 , J. P. Redorta8 , S. Daneshmand9 , S. A. Hussain1,2 , H. J. Cutuli 10 , G. Procopio 11 , V. Guadalupi 11 , N. Vasdev 12,13 , V. Naini 14 , L. Crow15 , S. Triantos 15 , M. Baig 15 & G. Steinberg16 , for the THOR-2 Cohort 1 Investigators
doi : 10.1016/j.annonc.2023.09.3116
Volume 35, Issue 1, January 2024, Pages 98-106
Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial☆
A. O. Siefker-Radtke1, N. Matsubara 2 , S. H. Park3 , R. A. Huddart4 , E. F. Burgess 5 , M. ?zgüroglu 6 , B. P. Valderrama 7 , B. Laguerre8 , U. Basso9 , S. Triantos 10 , S. Akapame 10 , Y. Kean10 , K. Deprince11 , S. Mukhopadhyay12 & Y. Loriot13 , for the THOR cohort 2 investigators
doi : 10.1016/j.annonc.2023.10.003
Volume 35, Issue 1, January 2024, Pages 107-117
Radioimmunotherapy versus autologous hematopoietic stem cell transplantation in relapsed/refractory follicular lymphoma: a Fondazione Italiana Linfomi multicenter, randomized, phase III trial
. Ladetto 1,2y, R. Tavarozzi 1,2y, M. Zanni 2 , A. Evangelista3 , S. Ferrero 4 , A. Tucci5 , B. Botto 6 , S. Bolis 7 , S. Volpetti 8 , V. R. Zilioli9 , B. Puccini 10 , A. Arcari11 , V. Pavone12 , G. Gaidano 2,13 , P. Corradini 14 , M. Tani 15 , F. Cavallo 4 , G. Milone 16 , C. Ghiggi 17 , A. Pinto18 , D. Pastore19 , A. J. M. Ferreri 20 , G. Latte 21 , C. Patti22 , F. Re23 , F. Benedetti24 , S. Luminari 25 , E. Pennese 26 , E. Bossi 7 , C. Boccomini 6 , A. Anastasia 5 , C. Bottelli5 , G. Ciccone 3 & U. Vitolo
doi : 10.1016/j.annonc.2023.10.095
Volume 35, Issue 1, January 2024, Pages 118-129
Metabolic tumor volume predicts outcome in patients with advanced stage follicular lymphoma from the RELEVANCE trial☆
A. S. Cottereau 1, L. Rebaud 2,3 , J. Trotman 4 , P. Feugier5 , L. J. Nastoupil 6 , E. Bachy7 , I. W. Flinn 8 , C. Haioun9 , L. Ysebaert 10 , N. L. Bartlett 11 , H. Tilly12,13 , O. Casasnovas 14,15 , R. Ricci 16 , C. Portugues16 , I. Buvat 2 , M. Meignan 17 & F. Morschhauser
doi : 10.1016/j.annonc.2023.10.121
Volume 35, Issue 1, January 2024, Pages 130-137
There is no place for ovarian cancer screening in hereditary breast–ovarian cancer syndromes
W. A. A. Tjalma
doi : 10.1016/j.annonc.2023.10.118
Volume 35, Issue 1, January 2024, Pages 138-139
Reply to the Letter to the Editor ‘There is no place for ovarian cancer screening in hereditary breast–ovarian cancer syndromes (in regard to “ESMO Clinical Practice Guideline on risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes�)’ by W. Tjalma
C. Sessa 1 & S. Paluch-Shimon 2 , on behalf of the ESMO Guidelines Committee*
doi : 10.1016/j.annonc.2023.10.119
Volume 35, Issue 1, January 2024, Pages 139-140
Misadjustment of post-trial life-prolonging therapies in the second interim analysis of the MAGNITUDE trial
P. Chen, M. Liu, G. Y. Li, F. Sun & T. Li*
doi : 10.1016/j.annonc.2023.10.128
Volume 35, Issue 1, January 2024, Pages 140-141
VP4-2023: Sotorasib 960 mg versus 240 mg in pretreated KRAS G12C advanced NSCLC
E. Carcereny4 , C. Dooms 5 , S-H. Lee 6 , E. M. Morocz 7 , T. Kato 8 , T-E. Ciuleanu 9 , G. Dy 10 , M. B. M. C. S. Parente 11 , K. J. O’Byrne 12 , Q. S-C. Chu 13 , G. De Castro Jr. 14 , N. Girard 15 , W. Snyder 16 , Q. Tran16 , W. Kormany 16 , B. Houk 16 & A.
doi : 10.1016/j.annonc.2023.10.790
Volume 35, Issue 1, January 2024, Pages 142-144
Erratum to “Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project�: [Annals of Oncology 32 (2021) 1626-1636]
D. M. Vega 1 , L. M. Yee2 , L. M. McShane2 , P. M. Williams 3 , L. Chen3 , T. Vilimas 3 , D. Fabrizio 4 , V. Funari 5 , J. Newberg4 , L. K. Bruce 5 , S.-J. Chen 6 , J. Baden7 , J. Carl Barrett8 , P. Beer9 , M. Butler10 , J.-H. Cheng 6 , J. Conroy11 , D. Cyanam 12 , K. Eyring 13 , E. Garcia 14 , G. Green 7 , V. R. Gregersen15 , M. D. Hellmann 16 , L. A. Keefer17 , L. Lasiter1 , A. J. Lazar 18 , M.-C. Li2 , L. E. MacConaill 14 , K. Meier19 , H. Mellert 20 , S. Pabla 11 , A. Pallavajjalla21 , G. Pestano20 , R. Salgado9 , R. Samara 15 , E. S. Sokol4 , P. Stafford22 , J. Budczies23 , A. Stenzinger23 , W. Tom12 , K. C. Valkenburg17 , X. Z. Wang 24 , V. Weigman 25 , M. Xie 8 , Q. Xie26 , A. Zehir16 , C. Zhao19 , Y. Zhao2 , M. D. Stewart 1 & J. Allen 1 , on behalf of the TMB Consortium
doi : 10.1016/j.annonc.2023.07.005
Volume 35, Issue 1, January 2024, Page 145
